The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus
Preclinical evidence has suggested a possible role for the 5-HT6 receptor in the treatment of cognitive dysfunction. However, currently there is little neurochemical evidence suggesting the mechanism(s) which may be involved. Using the selective 5-HT6 antagonist SB-271046 and in vivo microdialysis,...
Gespeichert in:
Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 2001-11, Vol.25 (5), p.662-668 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 668 |
---|---|
container_issue | 5 |
container_start_page | 662 |
container_title | Neuropsychopharmacology (New York, N.Y.) |
container_volume | 25 |
creator | Dawson, Lee A Nguyen, Huy Q Li, Ping |
description | Preclinical evidence has suggested a possible role for the 5-HT6 receptor in the treatment of cognitive dysfunction. However, currently there is little neurochemical evidence suggesting the mechanism(s) which may be involved. Using the selective 5-HT6 antagonist SB-271046 and in vivo microdialysis, we have evaluated the effects of this compound on the modulation of basal neurotransmitter release within multiple brain regions of the freely moving rat. SB-271046 produced no change in basal levels of dopamine (DA), norepinephrine (NE) or 5-HT in the striatum, frontal cortex, dorsal hippocampus or nucleus accumbens. Similarly, this compound had no effect on excitatory neurotransmission in the striatum or nucleus accumbens. Conversely, SB-271046 produced 3- and 2-fold increases in extracellular glutamate levels in both frontal cortex and dorsal hippocampus, respectively. These effects were completely attenuated by infusion of tetrodotoxin but unaffected by the muscarinic antagonist, atropine. Here we demonstrate for the first time the selective enhancement of excitatory neurotransmission by SB-271046 in those brain regions implicated in cognitive and memory function, and provide mechanistic evidence in support of a possible therapeutic role for 5-HT6 receptor antagonists in the treatment of cognitive and memory dysfunction. |
doi_str_mv | 10.1016/S0893-133X(01)00265-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_225242346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893133X01002652</els_id><sourcerecordid>998368161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-c01a457a72207d6110a8f573fbe29f361224cc9810b8861980a60848ad7f38503</originalsourceid><addsrcrecordid>eNqFkEFrFDEYhoMouFZ_ghDEgx5Gvy_JZDInqcvWFYpCd4XeQprJ2JTZZEyypXv2j5t2ix49fZfnfV--h5DXCB8QUH7cgOp5g5xfvgN8D8Bk27AnZIGdgEZycfmULP4iz8mLnG8AsO2kWpDf22tH22a9lfTCWTeXmOhpKOZnDD4XuvncsA5BSLpxk7PF37rpQFfh2gTrMl3dWV9MzRzoN7dPsSQT8s7n7GOgPtBSyy9MoWcp1s6JLmMq7o6aMNC1n-dozW7e55fk2Wim7F493hPy42y1Xa6b8-9fvi5PzxsrEEpjAY1oO9MxBt0gEcGose34eOVYP3KJjAlre4VwpZTEXoGRoIQyQzdy1QI_IW-OvXOKv_YuF30T9ynUSc1YywTjQlaoPUI2xZyTG_Wc_M6kg0bQ97r1g25971ID6gfdmtXc28dyk62ZxmrC-vwvjAJE31fs0xFz9dFb75LO1rsqc_Cp-tVD9P8Z-gOMy5LO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225242346</pqid></control><display><type>article</type><title>The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dawson, Lee A ; Nguyen, Huy Q ; Li, Ping</creator><creatorcontrib>Dawson, Lee A ; Nguyen, Huy Q ; Li, Ping</creatorcontrib><description>Preclinical evidence has suggested a possible role for the 5-HT6 receptor in the treatment of cognitive dysfunction. However, currently there is little neurochemical evidence suggesting the mechanism(s) which may be involved. Using the selective 5-HT6 antagonist SB-271046 and in vivo microdialysis, we have evaluated the effects of this compound on the modulation of basal neurotransmitter release within multiple brain regions of the freely moving rat. SB-271046 produced no change in basal levels of dopamine (DA), norepinephrine (NE) or 5-HT in the striatum, frontal cortex, dorsal hippocampus or nucleus accumbens. Similarly, this compound had no effect on excitatory neurotransmission in the striatum or nucleus accumbens. Conversely, SB-271046 produced 3- and 2-fold increases in extracellular glutamate levels in both frontal cortex and dorsal hippocampus, respectively. These effects were completely attenuated by infusion of tetrodotoxin but unaffected by the muscarinic antagonist, atropine. Here we demonstrate for the first time the selective enhancement of excitatory neurotransmission by SB-271046 in those brain regions implicated in cognitive and memory function, and provide mechanistic evidence in support of a possible therapeutic role for 5-HT6 receptor antagonists in the treatment of cognitive and memory dysfunction.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1016/S0893-133X(01)00265-2</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>5-HT6 receptor ; Anxiety ; Behavior ; Biological and medical sciences ; Brain research ; Cognition ; Dorsal hippocampus ; Frontal cortex ; Glutamate ; Medical sciences ; Memory ; Microdialysis ; Neuropharmacology ; Neurosciences ; Neurotransmitters. Neurotransmission. Receptors ; Nucleus accumbens ; Pharmacology. Drug treatments ; SB-271046 ; Serotoninergic system ; Striatum</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2001-11, Vol.25 (5), p.662-668</ispartof><rights>2001</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Nov 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-c01a457a72207d6110a8f573fbe29f361224cc9810b8861980a60848ad7f38503</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1140499$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Dawson, Lee A</creatorcontrib><creatorcontrib>Nguyen, Huy Q</creatorcontrib><creatorcontrib>Li, Ping</creatorcontrib><title>The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus</title><title>Neuropsychopharmacology (New York, N.Y.)</title><description>Preclinical evidence has suggested a possible role for the 5-HT6 receptor in the treatment of cognitive dysfunction. However, currently there is little neurochemical evidence suggesting the mechanism(s) which may be involved. Using the selective 5-HT6 antagonist SB-271046 and in vivo microdialysis, we have evaluated the effects of this compound on the modulation of basal neurotransmitter release within multiple brain regions of the freely moving rat. SB-271046 produced no change in basal levels of dopamine (DA), norepinephrine (NE) or 5-HT in the striatum, frontal cortex, dorsal hippocampus or nucleus accumbens. Similarly, this compound had no effect on excitatory neurotransmission in the striatum or nucleus accumbens. Conversely, SB-271046 produced 3- and 2-fold increases in extracellular glutamate levels in both frontal cortex and dorsal hippocampus, respectively. These effects were completely attenuated by infusion of tetrodotoxin but unaffected by the muscarinic antagonist, atropine. Here we demonstrate for the first time the selective enhancement of excitatory neurotransmission by SB-271046 in those brain regions implicated in cognitive and memory function, and provide mechanistic evidence in support of a possible therapeutic role for 5-HT6 receptor antagonists in the treatment of cognitive and memory dysfunction.</description><subject>5-HT6 receptor</subject><subject>Anxiety</subject><subject>Behavior</subject><subject>Biological and medical sciences</subject><subject>Brain research</subject><subject>Cognition</subject><subject>Dorsal hippocampus</subject><subject>Frontal cortex</subject><subject>Glutamate</subject><subject>Medical sciences</subject><subject>Memory</subject><subject>Microdialysis</subject><subject>Neuropharmacology</subject><subject>Neurosciences</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Nucleus accumbens</subject><subject>Pharmacology. Drug treatments</subject><subject>SB-271046</subject><subject>Serotoninergic system</subject><subject>Striatum</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkEFrFDEYhoMouFZ_ghDEgx5Gvy_JZDInqcvWFYpCd4XeQprJ2JTZZEyypXv2j5t2ix49fZfnfV--h5DXCB8QUH7cgOp5g5xfvgN8D8Bk27AnZIGdgEZycfmULP4iz8mLnG8AsO2kWpDf22tH22a9lfTCWTeXmOhpKOZnDD4XuvncsA5BSLpxk7PF37rpQFfh2gTrMl3dWV9MzRzoN7dPsSQT8s7n7GOgPtBSyy9MoWcp1s6JLmMq7o6aMNC1n-dozW7e55fk2Wim7F493hPy42y1Xa6b8-9fvi5PzxsrEEpjAY1oO9MxBt0gEcGose34eOVYP3KJjAlre4VwpZTEXoGRoIQyQzdy1QI_IW-OvXOKv_YuF30T9ynUSc1YywTjQlaoPUI2xZyTG_Wc_M6kg0bQ97r1g25971ID6gfdmtXc28dyk62ZxmrC-vwvjAJE31fs0xFz9dFb75LO1rsqc_Cp-tVD9P8Z-gOMy5LO</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Dawson, Lee A</creator><creator>Nguyen, Huy Q</creator><creator>Li, Ping</creator><general>Elsevier Inc</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20011101</creationdate><title>The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus</title><author>Dawson, Lee A ; Nguyen, Huy Q ; Li, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-c01a457a72207d6110a8f573fbe29f361224cc9810b8861980a60848ad7f38503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>5-HT6 receptor</topic><topic>Anxiety</topic><topic>Behavior</topic><topic>Biological and medical sciences</topic><topic>Brain research</topic><topic>Cognition</topic><topic>Dorsal hippocampus</topic><topic>Frontal cortex</topic><topic>Glutamate</topic><topic>Medical sciences</topic><topic>Memory</topic><topic>Microdialysis</topic><topic>Neuropharmacology</topic><topic>Neurosciences</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Nucleus accumbens</topic><topic>Pharmacology. Drug treatments</topic><topic>SB-271046</topic><topic>Serotoninergic system</topic><topic>Striatum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dawson, Lee A</creatorcontrib><creatorcontrib>Nguyen, Huy Q</creatorcontrib><creatorcontrib>Li, Ping</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dawson, Lee A</au><au>Nguyen, Huy Q</au><au>Li, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><date>2001-11-01</date><risdate>2001</risdate><volume>25</volume><issue>5</issue><spage>662</spage><epage>668</epage><pages>662-668</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>Preclinical evidence has suggested a possible role for the 5-HT6 receptor in the treatment of cognitive dysfunction. However, currently there is little neurochemical evidence suggesting the mechanism(s) which may be involved. Using the selective 5-HT6 antagonist SB-271046 and in vivo microdialysis, we have evaluated the effects of this compound on the modulation of basal neurotransmitter release within multiple brain regions of the freely moving rat. SB-271046 produced no change in basal levels of dopamine (DA), norepinephrine (NE) or 5-HT in the striatum, frontal cortex, dorsal hippocampus or nucleus accumbens. Similarly, this compound had no effect on excitatory neurotransmission in the striatum or nucleus accumbens. Conversely, SB-271046 produced 3- and 2-fold increases in extracellular glutamate levels in both frontal cortex and dorsal hippocampus, respectively. These effects were completely attenuated by infusion of tetrodotoxin but unaffected by the muscarinic antagonist, atropine. Here we demonstrate for the first time the selective enhancement of excitatory neurotransmission by SB-271046 in those brain regions implicated in cognitive and memory function, and provide mechanistic evidence in support of a possible therapeutic role for 5-HT6 receptor antagonists in the treatment of cognitive and memory dysfunction.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><doi>10.1016/S0893-133X(01)00265-2</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0893-133X |
ispartof | Neuropsychopharmacology (New York, N.Y.), 2001-11, Vol.25 (5), p.662-668 |
issn | 0893-133X 1740-634X |
language | eng |
recordid | cdi_proquest_journals_225242346 |
source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | 5-HT6 receptor Anxiety Behavior Biological and medical sciences Brain research Cognition Dorsal hippocampus Frontal cortex Glutamate Medical sciences Memory Microdialysis Neuropharmacology Neurosciences Neurotransmitters. Neurotransmission. Receptors Nucleus accumbens Pharmacology. Drug treatments SB-271046 Serotoninergic system Striatum |
title | The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T02%3A25%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%205-HT6%20Receptor%20Antagonist%20SB-271046%20Selectively%20Enhances%20Excitatory%20Neurotransmission%20in%20the%20Rat%20Frontal%20Cortex%20and%20Hippocampus&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Dawson,%20Lee%20A&rft.date=2001-11-01&rft.volume=25&rft.issue=5&rft.spage=662&rft.epage=668&rft.pages=662-668&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1016/S0893-133X(01)00265-2&rft_dat=%3Cproquest_cross%3E998368161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225242346&rft_id=info:pmid/&rft_els_id=S0893133X01002652&rfr_iscdi=true |